Pharmacokinetic Determinants of Virological Response to Raltegravir in the In Vitro Pharmacodynamic Hollow-Fiber Infection Model System

Por Brown, Ashley N., Adams, Jonathan R., Baluya, Dodge L., Drusano, George L.
Publicado no Antimicrob Agents Chemother (2015)

Zanamivir, at 600 Milligrams Twice Daily, Inhibits Oseltamivir-Resistant 2009 Pandemic H1N1 Influenza Virus in an In Vitro Hollow-Fiber Infection Model System

Por Brown, Ashley N., McSharry, James J., Weng, Qingmei, Adams, Jonathan R., Kulawy, Robert, Drusano, George L.
Publicado em 2011

Effect of Half-Life on the Pharmacodynamic Index of Zanamivir against Influenza Virus Delineated by a Mathematical Model

Por Brown, Ashley N., Bulitta, Jürgen B., McSharry, James J., Weng, Qingmei, Adams, Jonathan R., Kulawy, Robert, Drusano, George L.
Publicado em 2011

Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a Novel In Vitro Pharmacodynamic System

Por Brown, Ashley N., McSharry, James J., Adams, Jonathan R., Kulawy, Robert, Barnard, Richard J. O., Newhard, W., Corbin, A., Hazuda, Daria J., Louie, Arnold, Drusano, George L.
Publicado em 2012

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy

Por Brown, Ashley N., Drusano, George L., Adams, Jonathan R., Rodriquez, Jaime L., Jambunathan, Kalyani, Baluya, Dodge L., Brown, David L., Kwara, Awewura, Mirsalis, Jon C., Hafner, Richard, Louie, Arnold
Publicado no mBio (2015)